Product Description
Mechanisms of Action: M1 Antagonist,S1R Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Brazil | China | Egypt | Finland | France | Greece | Hong Kong | Italy | Korea | Portugal | Saudi Arabia | Slovakia | Slovenia | South Africa | Sweden | Taiwan | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT02183649 | P1 |
Completed |
Healthy Volunteers |
2009-12-01 |